Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Scancell Holdings ( (GB:SCLP) ) is now available.
Scancell Holdings has announced positive updated data from its SCOPE Phase 2 trial, demonstrating that its iSCIB1+ therapy, in combination with standard checkpoint inhibitors, significantly improves progression-free survival (PFS) in patients with advanced melanoma. The PFS rate of 74% at 16 months surpasses the standard of care’s 50% at 11.5 months, and early overall survival data shows a 14% improvement. These results support further development of iSCIB1+ for late-stage trials, with regulatory feedback aligning on trial design and endpoints. The announcement positions Scancell favorably in the immunotherapy market, potentially redefining the standard of care for melanoma and enhancing patient outcomes.
Spark’s Take on GB:SCLP Stock
According to Spark, TipRanks’ AI Analyst, GB:SCLP is a Neutral.
Scancell Holdings’ overall stock score is heavily influenced by its poor financial performance, characterized by zero revenue and significant losses. However, recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. Technical indicators suggest a mixed trend with short-term bullish momentum, though overbought conditions warrant caution. Valuation remains unattractive, reflecting ongoing financial challenges. Overall, while there are promising developments in the pipeline, the company’s current financial challenges necessitate caution.
To see Spark’s full report on GB:SCLP stock, click here.
More about Scancell Holdings
Scancell Holdings plc is a clinical stage biotechnology company focused on developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumor-specific immunity. Their lead product, iSCIB1+, is part of their DNA ImmunoBody® platform and is being tested in a Phase 2 trial for melanoma. Additionally, Scancell is exploring other immunotherapy products, such as Modi-1 from their Moditope® platform, and has established GlyMab Therapeutics Ltd. to develop high affinity GlyMab® antibodies targeting tumor-specific glycans.
Average Trading Volume: 1,005,238
Technical Sentiment Signal: Sell
Current Market Cap: £103.3M
Find detailed analytics on SCLP stock on TipRanks’ Stock Analysis page.